Joel Greenblatt's CAI Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 67,186 shares of Caris Life Sciences, Inc. (CAI) worth $1.81 M, representing 0.01% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Joel Greenblatt has initiated a new position in CAI, representing a fresh investment thesis on this company. Largest addition occurred in Q4 2025, adding 33,983 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Caris Life Sciences (CAI) Holding Value Over Time
Track share changes against reported price movement
Quarterly Caris Life Sciences (CAI) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +33,983 | Add 102.35% | 67,186 | $26.98 |
| Q3 2025 | +33,203 | New Buy | 33,203 | $30.25 |
Joel Greenblatt's Caris Life Sciences Investment FAQs
Joel Greenblatt first purchased Caris Life Sciences, Inc. (CAI) in Q3 2025, acquiring 33,203 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Caris Life Sciences, Inc. (CAI) for 2 quarters since Q3 2025.
Joel Greenblatt's largest addition to Caris Life Sciences, Inc. (CAI) was in Q4 2025, adding 67,186 shares worth $1.81 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 67,186 shares of Caris Life Sciences, Inc. (CAI), valued at approximately $1.81 M.
As of the Q4 2025 filing, Caris Life Sciences, Inc. (CAI) represents approximately 0.01% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Caris Life Sciences, Inc. (CAI) was 67,186 shares, as reported at the end of Q4 2025.